肿瘤型丙酮酸激酶M2在胰腺癌中的表达特点及其临床病理联系

Expression of tumour pyruvate kinase type M2 on pancreatic cancer and it's clinicopathologic connection

目的探讨肿瘤型丙酮酸激酶M2(M2-PK)在胰腺癌组织中的表达特点及其临床病理联系。方法 35例取自2004年1月至2007年6月在我院行手术治疗的经病理学证实为胰腺癌的患者的手术切除标本,切片用抗肿瘤型M2-PK抗体进行免疫组化染色,肿瘤细胞细胞质内出现黄染都被判为阳性,采用半定量法将染色强度分为未染色、弱阳性和强阳性三个等级,阳性细胞所占比例分为0、<30%、30%～60%、>60%和100%五个等级。结果 35例标本中染色阳性细胞比例均为100%,肿瘤细胞呈弱强度染色者7例,强染色者28例。高中低分化标本中强阳性例数所占比例分别为72.7%、83.3%和83.3%,淋巴结阴性和阳性标本中强阳性例数所占比例均为80.0%,无远处转移和有远处转移标本中强阳性比例均为80.0%,临床分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期标本中强阳性比例分别为85.7%、76.5%、83.3%和80.0%,以上差异均没有统计学意义。结论肿瘤型M2-PK在胰腺癌组织中呈高表达,但其表达强度与临床病理无明显相关性。

Objective To investigate the expression of tumour pyruvate kinase type M2 (tumour M2-PK)on pancreatic cancer and the connection between the expression of tumour M2-PK and the clinicopathologic manifestations.Methods 35 cases were selected from patients who were conducted operations in our hospital from January 2004 to June 2007 and were pathologically diagnosed pancreatic cancer.Sections were stained immunohistochemically with antibody to tumour M2-PK.Positive stain was defined as yellow stain in the cytoplasm.Intensity of stain was divided into no stain,poor stain and strong stain,and proportion of cells with positive stain was divided into 0,<30%,30%-60%,>60% and 100% by the semiquantitative method.Results All 35 cases showed 100% staining,of which 7 were weakly stained while other 28 were strongly stained.No differences were detected among different pathological classifications,clinical stages,lymph node involvement or distal metastasis.The proportions of cells with strong stain were 72.7%,83.3% and 83.3% in the well,moderately and poorly differentiated specimen respectively,and were both 80% in the specimen with and without lymph node or distant metastasis,and were 85.7%,76.5%,83.3% and 80.0% in the specimen of clinical stage Ⅰ,Ⅱ,Ⅲ and Ⅳ respectively.None of the differences was statistical significant.Conclusions Tumour M2-PK was highly expressed in pancreatic cancer,but there was no association between the expression of tumour M2-PK and the clinicopathologic manifestations.